Literature DB >> 21219581

Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation in Japanese registry.

H Egawa1, Y Ueda, T Ichida, S Teramukai, Y Nakanuma, S Onishi, H Tsubouchi.   

Abstract

The outcomes of primary sclerosing cholangitis (PSC) after living donor liver transplantation (LDLT) in a large series have not been reported. We aimed to determine long-term patient and graft survival, risk factors for PSC recurrence, and the significance of recurrence after LDLT in a Japanese registry. Questionnaires concerning patient characteristics, treatments, and clinical courses were used. Data of 114 patients undergoing primary LDLT for PSC from July 1996 to December 2008 in 29 institutions were evaluated. For strict diagnoses of recurrence, patients with hepatic artery thrombosis (n = 8), ABO-blood-type-incompatible transplantation (n = 8), and established ductopenic rejection (n = 2) were excluded and 96 patients were analyzed for risk factors. Recurrence was diagnosed in 26 patients (27%) at 8 to 79 months after transplantation. Patient, graft, and recurrence-free survivals were 78, 74 and 57% at 5 years after LDLT, respectively. The graft loss rate was 69 versus 23% in patients with versus without recurrence, respectively. Multivariate analysis revealed that high MELD scores, first-degree-relative donors, postoperative CMV infection, and early biliary anastomotic complications were significant risk factors for recurrence. PSC recurrence was a significant risk factor of graft loss but not patient death. PSC recurrence was frequent and had significant impacts on outcomes after LDLT. ©2011 The Authors Journal compilation©2011 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Year:  2011        PMID: 21219581     DOI: 10.1111/j.1600-6143.2010.03402.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  15 in total

Review 1.  Primary sclerosing cholangitis: is any treatment worthwhile?

Authors:  Ashley Barnabas; Roger W Chapman
Journal:  Curr Gastroenterol Rep       Date:  2012-02

Review 2.  Primary sclerosing cholangitis as an intractable disease.

Authors:  Sumihito Tamura; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  Intractable Rare Dis Res       Date:  2012-02

3.  Complete response to post-transplant lymphoproliferative disorder by surgical resection and rituximab after living-donor liver re-transplantation for recurrent primary sclerosing cholangitis.

Authors:  Koichiro Haruki; Hiroaki Shiba; Junichi Shimada; Norimitsu Okui; Tomonori Iida; Katsuhiko Yanaga
Journal:  Clin J Gastroenterol       Date:  2016-10-31

Review 4.  Liver Transplantation for Cholestatic Liver Diseases in Adults.

Authors:  Vandana Khungar; David Seth Goldberg
Journal:  Clin Liver Dis       Date:  2015-10-23       Impact factor: 6.126

5.  Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: Comparison of risk factors between living and deceased donor recipients.

Authors:  Fredric D Gordon; David S Goldberg; Nathan P Goodrich; Anna S F Lok; Elizabeth C Verna; Nazia Selzner; R Todd Stravitz; Robert M Merion
Journal:  Liver Transpl       Date:  2016-08-02       Impact factor: 5.799

Review 6.  Recent developments in the management of idiopathic cholestatic liver disease.

Authors:  Mohamad H Imam; Emma Weeding; Keith D Lindor
Journal:  Ann Gastroenterol       Date:  2012

7.  Long-term Prognosis and Recurrence of Primary Sclerosing Cholangitis After Liver Transplantation: A Single-Center Experience.

Authors:  Yoshihide Ueda; Toshimi Kaido; Hideaki Okajima; Koichiro Hata; Takayuki Anazawa; Atsushi Yoshizawa; Shintaro Yagi; Kojiro Taura; Toshihiko Masui; Noriyo Yamashiki; Hironori Haga; Miki Nagao; Hiroyuki Marusawa; Hiroshi Seno; Shinji Uemoto
Journal:  Transplant Direct       Date:  2017-11-20

8.  Rituximab Induction to Prevent the Recurrence of PSC After Liver Transplantation-The Lessons Learned From ABO-Incompatible Living Donor Liver Transplantation.

Authors:  Yohei Yamada; Ken Hoshino; Yasushi Fuchimoto; Kentaro Matsubara; Taizo Hibi; Hiroshi Yagi; Yuta Abe; Masahiro Shinoda; Minoru Kitago; Hideaki Obara; Takahito Yagi; Hideaki Okajima; Toshimi Kaido; Shinji Uemoto; Tatsuya Suzuki; Keiichi Kubota; Tomoharu Yoshizumi; Yoshihiko Maehara; Yukihiro Inomata; Yuko Kitagawa; Hiroto Egawa; Tatsuo Kuroda
Journal:  Transplant Direct       Date:  2018-02-02

Review 9.  Autoimmune Liver Disease Post-Liver Transplantation: A Summary and Proposed Areas for Future Research.

Authors:  Catherine Edmunds; Udeme D Ekong
Journal:  Transplantation       Date:  2016-03       Impact factor: 4.939

Review 10.  Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.

Authors:  Hitoshi Yoshiji; Sumiko Nagoshi; Takemi Akahane; Yoshinari Asaoka; Yoshiyuki Ueno; Koji Ogawa; Takumi Kawaguchi; Masayuki Kurosaki; Isao Sakaida; Masahito Shimizu; Makiko Taniai; Shuji Terai; Hiroki Nishikawa; Yoichi Hiasa; Hisashi Hidaka; Hiroto Miwa; Kazuaki Chayama; Nobuyuki Enomoto; Tooru Shimosegawa; Tetsuo Takehara; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2021-07-07       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.